Skip to main content

Table 2 Safety measures at visit 1 and visit 2 in patients receiving chicory

From: Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee

Variable Measured Cohort 1 Cohort 2 Cohort 3
  (N = 4)* (N = 4) (N = 13)
  Visit 1 Visit 2 P** Visit 1 Visit 2 P Visit 1 Visit 2 P
BP Syst (mm Hg) 136 ± 9.3 128 ± 9.9 0.40 144 ± 7.8 141 ± 3.5 0.80 138 ± 5.7 142 ± 5.4 0.39
BP Diast (mm Hg) 83 ± 6.6 82 ± 5.5 0.86 78 ± 10.1 88 ± 3.7 0.46 96 ± 2.3 88 ± 3.4 0.04
HR (BPM) 69 ± 4.2 77 ± 4.6 0.01 74 ± 9.2 76 ± 9.4 0.74 72 ± 3.7 71 ± 4.3 0.65
WBC (cell/mm3) 6.1 ± 0.6 6.1 ± 0.3 0.48 6.6 ± 1.2 5.9 ± 0.9 0.20 6.9 ± 0.5 6.6 ± 0.2 0.34
Hgb (g/dL) 12.8 ± 0.8 12.6 ± 0.7 0.23 14.4 ± 0.9 14.5 ± 0.8 0.25 14.6 ± 0.2 14.1 ± 0.3 0.02
Creatinine (mg/dL) 0.78 ± 0.08 0.78 ± 0.07 1 0.68 ± 0.11 0.70 ± 0.11 0.39 0.83 ± 0.04 0.84 ± 0.04 0.67
AST (U/L) 17.3 ± 1.8 17.8 ± 0.5 0.81 24.0 ± 3.5 25.0 ± 5.0 0.57 21.9 ± 2.4 22.3 ± 2.4 0.86
  1. * Patients included in this analysis were those receiving chicory who had lab values available at both baseline and final visits. Values represent mean and S.E.M.
  2. ** P values calculated using paired t-test, V1 vs V2.
  3. Normal range: WBC 4.1-11.1 × 10/μL.